- Home
- / Pharmstandard
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Pharmstandard financials data including stock price, CreditSafe score, income statement, balance sheet, cash flow, and acquistions and subsidiaries.
Revenue
₽142.9 B
FY, 2023
CreditSafe Score
?
Score changed on Oct 06, 2024
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| RUB | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|
| Revenue | 145.3B | 135.0B | 142.9B |
| Cost of goods sold | 112.2B | 98.8B | 109.3B |
| Gross profit | 33.0B | 36.2B | 33.6B |
| Gross profit margin, % | 22.7% | 26.8% | 23.5% |
| General and administrative expense | 2.9B | 3.4B | 4.3B |
| Operating expense total | 7.8B | 9.4B | 9.7B |
| EBIT | 25.3B | 26.8B | 23.9B |
| EBIT margin, % | 17.4% | 19.8% | 16.7% |
| Investment income | 8.8B | 28.1B | 261.2M |
| Interest income | 3.0B | 5.7B | 3.9B |
| Interest expense | 696.2M | 1.6B | 792.2M |
| Pre tax profit | 28.8B | 54.5B | 30.0B |
| Income tax expense | 4.1B | 5.2B | 6.7B |
| Net Income | 24.6B | 49.2B | 23.3B |
Acquisitions & Subsidiaries
| Company name | Date | Deal size |
|---|---|---|
| Lorem | Dec 23, 2021 | $40.0M |
| Ipsum | Jan 18, 2022 | $30.0M |
| Lorem Ipsum | Feb 18, 2022 | $25.0M |
| Dolor | Oct 21, 2021 | $60.0M |
Premium Content only available in Craft’s Intelligence Portal View acquisitions and subsidiaries by company, date, and deal size. Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. Learn more |